Semaglutide mastery course
Unit 4 of 12
Type 2 diabetes control
Semaglutide began as a diabetes drug, and the diabetes evidence is deep. The SUSTAIN (injectable) and PIONEER (oral) pr…
Glycemic control across the SUSTAIN and PIONEER programs
Semaglutide began as a diabetes drug, and the diabetes evidence is deep. The SUSTAIN (injectable) and PIONEER (oral) programs tested it against placebo and active comparators across many randomized trials.
This unit walks the glycemic results: how much HbA1c falls, how that compares to other agents, and why gradual titration and gastrointestinal tolerability shape real-world persistence.